Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 in advanced melanoma after standard therapy failure
CTR20181881Phase 2Completed
- Sponsor
- Taizhou Hanzhong Biomedical
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in melanoma, sponsored by Taizhou Hanzhong Biomedical. Started Oct 2018; status: completed.
02
Drugs
pucotenlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20181881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181881.